Dr Emily Eaton

Emily joined Sygnature in 2012 and has held several scientific and commercial roles within the business prior to being appointed as VP, Commercial Services in 2023. Owing to her blend of commercial and integrated discovery experience, Emily is uniquely positioned to bridge the commercial and scientific operations functions, ensuring customer-centric commercial engagement to drive successful collaborations and project delivery.

Emily has over 10 years of drug discovery experience and has supported projects from proof of concept to candidate drug selection, across multiple therapeutic areas and target classes.

Emily has a BSc (Hons.) in biochemistry and a PhD in telomere biology from the University of Nottingham.

 

LinkedIn Profile: https://www.linkedin.com/in/emily-eaton-32632021/

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…